Canadian Observational AntiPlatelet Study (COAPT):
Description of the Length of Dual Antiplatelet Therapy, Patient Characteristics, Treatment Patterns, and Processes of Care in Canadian Patients with Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Prospective, observational longitudinal study of 2,200 MI patients undergoing PCI with a follow-up period of 15 months

Co-Principal Investigators: Shamir Mehta and Shaun Goodman
Study Sponsor: Eli Lilly Canada
Oral Antiplatelet Therapies at Admission
(n=1,576 MI patients undergoing PCI at 26 Canadian hospitals; Dec 2011-Apr 2013)

- Median age 60 (53, 67) years
- 21% female
- 62% STEMI, 38% NSTEMI
- Initial oral antiplatelet therapy:
  - First dose of ADP receptor inhibitor therapy started in the Emergency Department in 75%
  - Clopidogrel 90%
  - Prasugrel 10%
  - Ticagrelor 15%
  - Among pts receiving prasugrel or ticagrelor, 62% also received clopidogrel

Abstract submitted by Dery et al
In-Hospital Switching of ADP Receptor Inhibitor in MI and PCI

TRANSLATE-ACS population
April 2010 to August 2012
8149 patients from 217 hospitals

Initial 1st gen ADPri (n=6077)
- No Switch (n=5408) (89%)
- Switch to 2nd gen (n=669) (11%)

Initial 2nd gen ADPri (n=2072)(25%)
- No Switch (n=1801) (87%)
- Switch to 1st gen (n=271) (13%)

In-hospital ADPri switching not associated with 6-week adverse cardiovascular events or hospitalization for bleeding

Bagai et al for the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome Investigators Circulation 2012;Abstract
Pre-loading with Clopidogrel in Patients with ACS Undergoing PCI

Clopidogrel pre-load (300-600 mg) (n=90)

No pre-load (n=516)

Prasugrel 60 mg load pre-PCI in ACS patients (n=606) → 10 mg daily maintenance

More patients with a clopidogrel pre-load had troponin elevation (80% vs. 31%) and cardiogenic shock (6.4% vs. 1.6%)

Loh et al Am J Cardiol 2013;111:841-45